DUBLIN, Ireland, May 19, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that data from multiple quality of life studies in patients with AL amyloidosis will be highlighted at The European Hematology Association (EHA) 21st Congress to be held June 9-12 in Copenhagen, Denmark.
"We look forward to sharing these qualitative and quantitative data that advances the understanding of the impact of AL amyloidosis on patients' lives at the upcoming EHA congress," commented Dale Schenk, PhD, President and Chief Executive Officer of Prothena, "Our commitment to the amyloidosis community involves not only research and development towards the goal of developing a new therapy indicated for AL amyloidosis, but also a commitment to understanding the impact of this devastating disease on patients' quality of life."
Data that highlights a variety of aspects of quality of life in AL amyloidosis, including the relative burden of AL amyloidosis on health-related quality of life for patients, the impact of treatment-related symptoms on treatment compliance, impact on absenteeism, job productivity and loss, and validity of psychometric properties of the SF-36v2® Health Survey, will be presented in the following sessions:
(Abstract #P784) The Relative Burden of AL Amyloidosis on Health-related Quality of Life
(Abstract #E1445) Treatment History, Tolerability and Impact on Health-Related Quality of Life in AL Amyloidosis
(Abstract #E1458) The Impact of AL Amyloidosis on Absenteeism, Reduced Productivity and Job Loss
(Abstract #E1441) Psychometric Validation of the SF-36V2® Health Survey in an AL Amyloidosis Population
All e-Posters are available Friday, June 10, 9:30 to Saturday, June 11, 19:00 CET
About AL Amyloidosis
Systemic amyloidoses are a complex group of progressive diseases caused by tissue deposition of misfolded proteins that result in progressive organ damage. The most common type, AL amyloidosis or primary amyloidosis, involves a hematological disorder caused by plasma cells that produce misfolded immunoglobulin light chain resulting in deposits of abnormal AL protein (amyloid) in the tissues and organs of individuals with this disease. There are no approved treatments for AL amyloidosis, and none that directly target potentially toxic forms of the AL protein. AL amyloidosis is a rare disorder and it is estimated that about 30,000 to 45,000 patients in the U.S. and Europe suffer from this disease. Both the causes and origins of AL amyloidosis remain poorly understood. For more information on AL amyloidosis, please visit the websites of the Amyloidosis Support Group and the Amyloidosis Foundation.
Prothena Corporation plc is a global, late-stage clinical biotechnology company seeking to fundamentally change the course of progressive diseases with its clinical pipeline of novel therapeutic antibodies. Fueled by its deep scientific understanding built over decades of research in protein misfolding and cell adhesion — the root causes of many serious or currently untreatable amyloid and inflammatory diseases — Prothena has advanced several drug candidates into clinical trials while pursuing discovery of additional novel therapies. Our clinical pipeline of antibody-based product candidates targets a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002) and inflammatory diseases including psoriasis (PRX003).
This press release contains forward-looking statements. These statements relate to, among other things, our goal to develop a new therapy specifically indicated for AL amyloidosis. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to the risks, uncertainties and other factors described in the "Risk Factors" sections of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2016 and our subsequent Quarterly Reports on Form 10-Q filed with the SEC. Prothena undertakes no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events or changes in Prothena's expectations.
Contacts: Investors: Tran Nguyen, CFO 650-837-8535, IR@prothena.com Media: Ellen Rose, Head of Communications 650-922-2405, firstname.lastname@example.org